India pharma market sees 7.4 pc growth in April over surge in chronic therapies

IANS May 15, 2025 223 views

The Indian pharmaceutical market has demonstrated robust growth of 7.4% in April, primarily fueled by chronic therapy segments. Cardiac, central nervous system, and respiratory therapies played crucial roles in this expansion. Domestic pharmaceutical companies continue to lead the market, holding an impressive 83% market share. The growth reflects a combination of price increases, new product launches, and steady volume expansion across various therapeutic categories.

"Price hikes and new launches contribute significantly to pharma market growth" - Motilal Oswal Financial Services Report
New Delhi, May 15: Indian pharma market (IPM) has seen a 7.4 per cent year-on-year (YoY) growth in April due to a surge in chronic therapies, according to a report.

Key Points

1

Chronic therapies drive 9% year-on-year pharmaceutical market expansion

2

Indian companies dominate 83% market share

3

Cardiac and anticancer segments show strong performance

The monthly report by Motilal Oswal Financial Services showed that the IPM's growth in April 2024 was 9 per cent. In March 2025 it was 9.3 per cent.

The growth was driven by strong outperformance in cardiac, central Nervous System (CNS), and respiratory therapies.

Notably, respiratory therapies saw a revival in YoY growth in April. Acute therapy growth stood at 6 per cent in April (vs. 6 per cent in April 2024 and 8 per cent in March 2025) owing to seasonality.

IPM growth was also led by price (4.3 per cent), new launches (2.3 per cent), and volume growth (1.3 per cent).

Further, the report said that therapies like cardiac (11.3 per cent), gastro (9.4 per cent), antineoplast -- also known as anticancer drugs or chemotherapy drugs -- (12.6 per cent), and urology (13.1 per cent) lead YoY growth on a moving annual turnover (MAT) basis. On the MAT basis, the industry reported 7.9 per cent growth YoY.

Chronic therapies witnessed 9 per cent YoY growth, while acute therapies displayed 6 per cent YoY growth in April. The acute segment's share in overall IPM stood at 61 per cent for MAT April, with YoY growth of 7.9 per cent.

The report noted that domestic companies outperformed multinationals in April. As of April, Indian pharma companies hold a majority share of 83 per cent in IPM, while the remaining is held by multi-national pharma companies (MNCs). In March, Indian companies grew 7.4 per cent, while MNCs grew 7.4 per cent YoY.

Similarly, a recent report, by rating agency India Ratings and Research (Ind-Ra), showed that IPM continued its growth in April with 7.8 per cent YoY in revenue.

The report showed that the growth was driven by the price hikes taken by companies with volume growing 1.3 per cent YoY. Almost all major chronic therapies also showed positive value and volume growth.

Reader Comments

Here are 6 diverse Indian perspective comments for the pharma market growth article:
R
Rajesh K.
Great to see Indian pharma companies leading with 83% market share! 🇮🇳 Our domestic manufacturers have really stepped up quality while keeping medicines affordable. The growth in cardiac and cancer therapies shows how healthcare needs are changing in India.
P
Priya M.
While the numbers look positive, I'm concerned about the 4.3% price increase. Many middle-class families already struggle with medical costs. Hope the government monitors these price hikes carefully, especially for life-saving drugs.
A
Amit S.
The growth in chronic therapies reflects our changing lifestyle diseases. More sedentary jobs, stress, and urban pollution are taking a toll. We need better preventive healthcare along with these treatment options. #HealthForAll
S
Sunita R.
As someone whose father needs cardiac meds, I'm happy to see growth in this sector but worried about accessibility in rural areas. Pharma companies should focus on distribution networks beyond cities. Tier 2/3 towns need these medicines too!
V
Vikram J.
The 12.6% growth in anti-cancer drugs is bittersweet. On one hand, it shows better treatment availability. On the other, it reflects rising cancer cases. Government should invest more in early detection programs alongside supporting pharma growth.
N
Neha P.
Interesting to see respiratory therapies bouncing back. Probably due to the unpredictable weather and pollution levels across North India this year. Hope companies are also working on more affordable asthma medications for children. 🤧

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Your email won't be published


Disclaimer: Comments here reflect the author's views alone. Insulting or using offensive language against individuals, communities, religion, or the nation is illegal.

Tags:
Indian Pharmaceutical Market Healthcare Growth Chronic Therapies Motilal Oswal Pharma Sector